Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study

By Fariña-Sarasqueta Arantza   Lijnschoten Gesina   Rutten Harm   van den Brule Adriaan  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1167-1171

Springer Publishing Company

Access to resources Recommend Favorite

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

By Assersohn L.   Norman A.R.   Cunningham D.   Iveson T.   Seymour M.   Hickish T.   Massey A.   Prior Y.   Hill M.E.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1121-1128

Elsevier

Access to resources Recommend Favorite

A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage breast carcinoma

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 143-144

Informa Healthcare

Access to resources Recommend Favorite

Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously

By            

Oncology Letters, Vol. 3, Iss. 6, 2012-01 ,pp. : 1191-1194

Spandidos Publications

Access to resources Recommend Favorite

Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder

By Poortmans Philip M.   Richaud Pierre   Collette Laurence   Ho Goey S.   Pierart Marianne   Van Der Hulst Marleen   Bolla Michel    

Acta Oncologica, Vol. 47, Iss. 5, 2008-11 ,pp. : 937-940

Informa Healthcare

Access to resources Recommend Favorite